Dacomitinib

Cytostatic · Kinase Inhibitor

Indications

First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an approved test.

Dosage

Adults: 45 mg orally once daily with or without food. Children: Not recommended.

Adverse Effects

Most common adverse reactions are (incidence >20%) diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Precautions: Interstitial Lung Disease (ILD) permanently discontinue Dacomitinib if confirmed. If diarrhea or dermatologic adverse reactions withhold and reduce the dose of Dacomitinib based on the severity.

Interactions

Proton Pump Inhibitors (PPIs), locally-acting antacids or H2-receptor antagonist, CYP2D6 substrates.

Advice to Patient

Advise females of reproductive potential to use effective contraception.

Pharmacokinetics

Elimination: Mean (CV%). Plasma half-life: 70 hours (21%). Metabolism: Hepatic metabolism is the main route of clearance of dacomitinib. Excretion: 79% in feces (20% as dacomitinib) and 3% in urine.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.